FDA Approves Long-acting Injectable for Bipolar Disorder FDA Approves Long-acting Injectable for Bipolar Disorder
The FDA has approved extended-release injectable aripiprazole for maintenance monotherapy for bipolar disorder in adults.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena ® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 28, 2017 Category: Drugs & Pharmacology Source Type: news
Addition of Aripiprazole Ups Major Depressive Disorder Remission
Small increased likelihood of remission at 12 weeks in patients with major depressive disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Journal, Source Type: news
For Treatment-Resistant Depression, Add an Antipsychotic or Switch Antidepressants? (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
For patients with depression unresponsive to antidepressants, adding the antipsychotic aripiprazole seems modestly better than switching to the antidepressant bupropion, a JAMA study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 12, 2017 Category: Primary Care Source Type: news
Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant
(The JAMA Network Journals) Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 11, 2017 Category: International Medicine & Public Health Source Type: news
Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis
For children and adolescents with first-episode psychosis, the second generation antipsychotics quetiapine extended release and aripiprazole have equivalent efficacy, but different side effect profiles, according to a head-to-head comparison.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news
FDA Approves Longer-Acting Aripiprazole for Schizophrenia FDA Approves Longer-Acting Aripiprazole for Schizophrenia
The FDA has approved a 2-month dose of aripiprazole lauroxil extended-release injectable suspension for the treatment of schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 6, 2017 Category: Drugs & Pharmacology Source Type: news
Otsuka, Proteus resubmit FDA application for novel drug-device combination
One year after the FDA declined to approve Proteus Digital Health and Otsuka ' s new sensor-embedded formulation of Otsuka ' s antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. (Source: mobihealthnews)
Source: mobihealthnews - May 23, 2017 Category: Information Technology Source Type: news
MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Philips picks up airway clearance device dev RespirTech
Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount.
St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet.
The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news
aripiprazole (Abilify, Abilify Maintena, Aristrada)
Title: aripiprazole (Abilify, Abilify Maintena, Aristrada)Category: MedicationsCreated: 2/17/2004 12:00:00 AMLast Editorial Review: 5/1/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 1, 2017 Category: Drugs & Pharmacology Source Type: news
Improve Your Mood With Turmeric Root (Curcumin)
"Dr. Sears," C.R. asked me, "I know curcumin is good for treating a lot of things, but can it improve someone's mood?"
This morning, one of the women on my staff, C.R., came into my office to talk to me about her 15-year-old son. He'd been irritable and moody and sleeping a lot lately. Most mornings, he'd miss the bus to school and then stress about being late.
But today, he was up on time with his backpack packed and a smile on his face. C.R. even heard him whistling in the shower! And he was at the bus stop 10 minutes early.
C. R. started taking curcumin supplements a few weeks ago. She had no...
Source: Al Sears, MD Natural Remedies - March 21, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news
Abilify (Aripiprazole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 21, 2017 Category: Drugs & Pharmacology Source Type: news
We Must Fight Rhino Poaching With Science And Dismiss Superstition
A recent story about poachers breaking into the zoo in Paris and killing a rhino to saw off its horn has led to Czech and Belgian zookeepers pre-emptively sawing off the horns of their rhinos in captivity to thwart potential poachers.
That sort of supply-reduction thinking will work just as effectively as fumigating illicit cocaine crops and banning assault weapons. You cannot repeal the law of supply and demand. So long as there is demand for rhino horns, cocaine, and assault weapons, someone will step up to supply them.
The demand for cocaine and assault weapons seems easy to understand. But does everybody know why poach...
Source: Science - The Huffington Post - March 16, 2017 Category: Science Source Type: news
